|
GB1062357A
(en)
*
|
1965-03-23 |
1967-03-22 |
Pfizer & Co C |
Quinazolone derivatives
|
|
US4337341A
(en)
*
|
1976-11-02 |
1982-06-29 |
Eli Lilly And Company |
4a-Aryl-octahydro-1H-2-pyrindines
|
|
DE3815221C2
(de)
|
1988-05-04 |
1995-06-29 |
Gradinger F Hermes Pharma |
Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
|
|
US5698155A
(en)
|
1991-05-31 |
1997-12-16 |
Gs Technologies, Inc. |
Method for the manufacture of pharmaceutical cellulose capsules
|
|
RU2065438C1
(ru)
|
1993-12-22 |
1996-08-20 |
Институт химии природного органического сырья СО РАН |
Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
|
|
US6635626B1
(en)
|
1997-08-25 |
2003-10-21 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
US5998463A
(en)
|
1998-02-27 |
1999-12-07 |
Pfizer Inc |
Glycogen phosphorylase inhibitors
|
|
US6476032B2
(en)
|
1998-12-17 |
2002-11-05 |
Wyeth |
2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
|
|
PL352680A1
(en)
|
1999-06-03 |
2003-09-08 |
Knoll Gmbh |
Benzothiazinone and benzoxazinone compounds
|
|
FR2807660A1
(fr)
|
2000-04-13 |
2001-10-19 |
Warner Lambert Co |
Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
|
|
DE60215682T2
(de)
|
2001-09-27 |
2007-09-06 |
Smithkline Beecham Corp. |
AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
|
|
KR20030095729A
(ko)
|
2002-06-14 |
2003-12-24 |
크리스탈지노믹스(주) |
2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
WO2004032870A2
(en)
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
|
IL154370A0
(en)
*
|
2003-02-10 |
2003-09-17 |
Chemagis Ltd |
Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
|
|
JP4733023B2
(ja)
|
2003-04-16 |
2011-07-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
|
|
JP5335191B2
(ja)
|
2003-08-22 |
2013-11-06 |
デンドレオン コーポレイション |
Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
|
|
WO2008021463A2
(en)
|
2006-08-15 |
2008-02-21 |
Acadia Pharmaceuticals, Inc. |
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
|
|
SG152226A1
(en)
|
2004-04-07 |
2009-05-29 |
Rinat Neuroscience Corp |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
|
WO2006007864A1
(en)
|
2004-07-17 |
2006-01-26 |
Max Planck Geselllschaft Zur Förderung Der Wissenschaft |
Treating neurodegenerative conditions
|
|
US7671077B2
(en)
*
|
2004-07-19 |
2010-03-02 |
Leu-Fen Hou Lin |
Neuroprotective small organic molecules, compositions and uses related thereto
|
|
US7718674B2
(en)
|
2004-09-27 |
2010-05-18 |
Bridge Pharma, Inc. |
Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
|
|
US7820668B2
(en)
|
2005-01-19 |
2010-10-26 |
Eisai Inc. |
Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
|
|
FR2881138B1
(fr)
|
2005-01-27 |
2007-03-02 |
Servier Lab |
Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US20060257337A1
(en)
|
2005-04-28 |
2006-11-16 |
David Sherris |
Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
|
|
JP5191155B2
(ja)
|
2006-03-27 |
2013-04-24 |
大塚製薬株式会社 |
カルボスチリル化合物からなる医薬
|
|
JP2007303392A
(ja)
|
2006-05-11 |
2007-11-22 |
Honda Motor Co Ltd |
気体燃料内燃機関の制御装置
|
|
WO2008053863A1
(en)
|
2006-10-30 |
2008-05-08 |
Santen Pharmaceutical Co., Ltd. |
Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
|
|
EP2114948B1
(en)
|
2006-12-28 |
2014-06-25 |
AbbVie Inc. |
Inhibitors of poly(adp-ribose)polymerase
|
|
EP2176241B1
(en)
|
2007-08-17 |
2015-12-23 |
Hetero Drugs Limited |
A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
|
|
WO2009067197A2
(en)
|
2007-11-16 |
2009-05-28 |
Rayspan Corporation |
Filter design methods and filters based on metamaterial structures
|
|
WO2010077680A2
(en)
|
2008-12-08 |
2010-07-08 |
Vm Discovery Inc. |
Compositions of protein receptor tyrosine kinase inhibitors
|
|
EP2239256A1
(en)
*
|
2009-03-13 |
2010-10-13 |
Almirall, S.A. |
Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
|
|
US8853235B2
(en)
*
|
2009-11-23 |
2014-10-07 |
Senhwa Biosciences, Inc. |
Polymorphs and salts of a kinase inhibitor
|
|
EA201291346A1
(ru)
|
2010-06-23 |
2013-05-30 |
ОСИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Полиморфы osi-906
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
WO2012119079A1
(en)
|
2011-03-03 |
2012-09-07 |
Indiana University Research And Technology Corporation |
uPAR-uPA INTERACTION INHIBITORS AND METHODS FOR TREATING CANCER
|
|
US8999992B2
(en)
|
2013-03-15 |
2015-04-07 |
Vm Pharma Llc |
Crystalline forms of tryosine kinase inhibitors and their salts
|
|
WO2016043975A1
(en)
|
2014-09-17 |
2016-03-24 |
Vm Pharma Llc |
Crystalline forms of tyrosine kinase inhibitors and their salts
|